Cargando…

Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype

The accelerated risk of cardiovascular disease (CVD) in Rheumatoid Arthritis (RA) requires further study of the underlying pathophysiology and determination of the at-risk RA phenotype. Our objectives were to describe the cardiac structure and function and arterial stiffness, and association with di...

Descripción completa

Detalles Bibliográficos
Autores principales: Bissell, L. A., Erhayiem, B., Hensor, E. M. A., Fent, G., Burska, A., McDiarmid, A. K., Swoboda, P. P., Donica, H., Plein, S., Buch, M. H., Greenwood, J. P., Andrews, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080678/
https://www.ncbi.nlm.nih.gov/pubmed/32036488
http://dx.doi.org/10.1007/s10554-019-01714-6
_version_ 1783508040363802624
author Bissell, L. A.
Erhayiem, B.
Hensor, E. M. A.
Fent, G.
Burska, A.
McDiarmid, A. K.
Swoboda, P. P.
Donica, H.
Plein, S.
Buch, M. H.
Greenwood, J. P.
Andrews, J.
author_facet Bissell, L. A.
Erhayiem, B.
Hensor, E. M. A.
Fent, G.
Burska, A.
McDiarmid, A. K.
Swoboda, P. P.
Donica, H.
Plein, S.
Buch, M. H.
Greenwood, J. P.
Andrews, J.
author_sort Bissell, L. A.
collection PubMed
description The accelerated risk of cardiovascular disease (CVD) in Rheumatoid Arthritis (RA) requires further study of the underlying pathophysiology and determination of the at-risk RA phenotype. Our objectives were to describe the cardiac structure and function and arterial stiffness, and association with disease phenotype in patients with established) RA, in comparison to healthy controls, as measured by cardiovascular magnetic resonance imaging (CMR). 76 patients with established RA and no history of CVD/diabetes mellitus were assessed for RA and cardiovascular profile and underwent a non-contrast 3T-CMR, and compared to 26 healthy controls. A univariable analysis and multivariable linear regression model determined associations between baseline variables and CMR-measures. Ten-year cardiovascular risk scores were increased in RA compared with controls. Adjusting for age, sex and traditional cardiovascular risk factors, patients with RA had reduced left ventricular ejection fraction (mean difference − 2.86% (− 5.17, − 0.55) p = 0.016), reduced absolute values of mid systolic strain rate (p < 0.001) and lower late/active diastolic strain rate (p < 0.001) compared to controls. There was evidence of reduced LV mass index (LVMI) (− 4.56 g/m(2) (− 8.92, − 0.20), p = 0.041). CMR-measures predominantly associated with traditional cardiovascular risk factors; male sex and systolic blood pressure independently with increasing LVMI. Patients with established RA and no history of CVD have evidence of reduced LV systolic function and LVMI after adjustment for traditional cardiovascular risk factors; the latter suggesting cardiac pathology other than atherosclerosis in RA. Traditional cardiovascular risk factors, rather than RA disease phenotype, appear to be key determinants of subclinical CVD in RA potentially warranting more effective cardiovascular risk reduction programs.
format Online
Article
Text
id pubmed-7080678
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-70806782020-03-23 Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype Bissell, L. A. Erhayiem, B. Hensor, E. M. A. Fent, G. Burska, A. McDiarmid, A. K. Swoboda, P. P. Donica, H. Plein, S. Buch, M. H. Greenwood, J. P. Andrews, J. Int J Cardiovasc Imaging Original Paper The accelerated risk of cardiovascular disease (CVD) in Rheumatoid Arthritis (RA) requires further study of the underlying pathophysiology and determination of the at-risk RA phenotype. Our objectives were to describe the cardiac structure and function and arterial stiffness, and association with disease phenotype in patients with established) RA, in comparison to healthy controls, as measured by cardiovascular magnetic resonance imaging (CMR). 76 patients with established RA and no history of CVD/diabetes mellitus were assessed for RA and cardiovascular profile and underwent a non-contrast 3T-CMR, and compared to 26 healthy controls. A univariable analysis and multivariable linear regression model determined associations between baseline variables and CMR-measures. Ten-year cardiovascular risk scores were increased in RA compared with controls. Adjusting for age, sex and traditional cardiovascular risk factors, patients with RA had reduced left ventricular ejection fraction (mean difference − 2.86% (− 5.17, − 0.55) p = 0.016), reduced absolute values of mid systolic strain rate (p < 0.001) and lower late/active diastolic strain rate (p < 0.001) compared to controls. There was evidence of reduced LV mass index (LVMI) (− 4.56 g/m(2) (− 8.92, − 0.20), p = 0.041). CMR-measures predominantly associated with traditional cardiovascular risk factors; male sex and systolic blood pressure independently with increasing LVMI. Patients with established RA and no history of CVD have evidence of reduced LV systolic function and LVMI after adjustment for traditional cardiovascular risk factors; the latter suggesting cardiac pathology other than atherosclerosis in RA. Traditional cardiovascular risk factors, rather than RA disease phenotype, appear to be key determinants of subclinical CVD in RA potentially warranting more effective cardiovascular risk reduction programs. Springer Netherlands 2020-02-08 2020 /pmc/articles/PMC7080678/ /pubmed/32036488 http://dx.doi.org/10.1007/s10554-019-01714-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Paper
Bissell, L. A.
Erhayiem, B.
Hensor, E. M. A.
Fent, G.
Burska, A.
McDiarmid, A. K.
Swoboda, P. P.
Donica, H.
Plein, S.
Buch, M. H.
Greenwood, J. P.
Andrews, J.
Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype
title Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype
title_full Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype
title_fullStr Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype
title_full_unstemmed Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype
title_short Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype
title_sort cardiovascular mri evidence of reduced systolic function and reduced lv mass in rheumatoid arthritis: impact of disease phenotype
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080678/
https://www.ncbi.nlm.nih.gov/pubmed/32036488
http://dx.doi.org/10.1007/s10554-019-01714-6
work_keys_str_mv AT bissellla cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype
AT erhayiemb cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype
AT hensorema cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype
AT fentg cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype
AT burskaa cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype
AT mcdiarmidak cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype
AT swobodapp cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype
AT donicah cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype
AT pleins cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype
AT buchmh cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype
AT greenwoodjp cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype
AT andrewsj cardiovascularmrievidenceofreducedsystolicfunctionandreducedlvmassinrheumatoidarthritisimpactofdiseasephenotype